Beyond Signal Detection: Sequential Target Trial Emulations to Confirm Previously Detected Adverse Drug Event Signals for Atorvastatin in Older Medicare Beneficiaries

ImportanceActive pharmacovigilance via sequential target trial emulation can detect adverse drug event (ADE) signals missed by spontaneous reporting, yet signals identified through high-dimensional screening require rigorous, pre-specified confirmation that addresses residual confounding, outcome heterogeneity, multiplicity, and absolute risk. ObjectiveTo confirm or refute previously detected ADE signals associated with atorvastatin initiation among older adults by applying refined and more homogeneous outcome definitions, expanded family- and component-level exclusions, within-outcome false-d